ReviewFrontiers in immunology2026
Microbiological mechanisms of immune response modulation: clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human microbiota is a major regulator of immune development, mucosal barrier integrity, and systemic immune tone. Its effects are mediated by microbe-associated molecular patterns, pattern-recognition receptors, microbial metabolites such as short-chain fatty acids, tryptophan-derived indoles, secondary bile acids and vitamin-pathway metabolites, and direct interactions with epithelial and immune cells. A balanced microbiota supports regulatory T-cell responses, secretory IgA production, innate-like lymphocyte maturation and epithelial barrier function, whereas dysbiosis may promote barrier dysfunction, inflammatory polarization and abnormal responses to dietary, environmental or self-antigens. This narrative review integrates mechanistic and translational evidence across early-life immune maturation, innate and adaptive immune sensing, microbial metabolites, cross-kingdom interactions, gut-organ axes, immune-mediated diseases and microbiota-targeted interventions. Particular emphasis is placed on distinguishing mechanistic evidence from association. Although microbiome-directed therapies are promising, routine clinical translation requires standardized sampling and multi-omics workflows, controlled interventional studies, mechanistic validation, reproducible biomarkers and indication-specific evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.